BOSTON: A five-year, international study into the genetic roots of Alzheimer’s is expanding. The TOMMORROW study, which is going on in about 50 locations in North America, Europe and Australia, tests a drug — one used to control diabetes — to see whether it could prevent, or at least delay, the onset of Alzheimer’s disease.
Researchers also want to fine-tune understanding of who’s most likely to develop the disease based on genetics.
Participants must be ages 65-83, have no signs of Alzheimer’s and carry a set of genetic mutations that are believed to put them at risk for Alzheimer’s — something that a blood test at Quest will determine.